Managing Risk At Cochlear

Similar documents
For personal use only

January 30, 2018 Dow Wilson President and Chief Executive Officer

Cochlear Limited 2017 Annual General Meeting Chairman s Address

Cochlear Limited 2018 Annual General Meeting Chairman s Address

For personal use only

For personal use only

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Investor Presentation

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

Cochlear Limited 2007 Annual General Meeting

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Entific. Dan Pitulia CEO Entific Medical Systems

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Strategic Directions

STRATEGIC PLAN

GENETIC TECHNOLOGIES LIMITED

The Dental Corporation Opportunity

IMPROVING YOUR HEALTH AND SAFETY PERFORMANCE METRICS WITH OHSAS 18001

Cochlear Limited Results for the half year ended 31 December 2007

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

THE CHANGING PARADIGM EHS Information Driven Performance

Annual Shareholders Meeting

IT Foundation Application Map

Cochlear Limited Annual General Meeting. Mr Tommie Bergman. Chairman. Tuesday 21 st October 2008

LifeHealthcare Investor Day 5 October 2016

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

COCHLEAR NUCLEUS RELIABILITY REPORT. Volume 14 February 2016

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

Managing Global EHS Risk: A Solution. Katie Florio Alizabeth Aramowicz Smith July 19 th, 2017

Management Presentation. January 2019

BUILDING BUSINESS THROUGH SYNERGY

COCHLEAR NUCLEUS IMPLANT RELIABILITY REPORT. Volume 15 January 2017

COCHLEAR NUCLEUS IMPLANT RELIABILITY REPORT. Volume 16 December 2017

For personal use only

DuPont Nutrition & Health Craig Binetti, President

Innovative Finance: the power of innovation to save lives

The Oaktree Foundation s GENERATE PROGRAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

Shareholder Presentation Annual Meeting 2018

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Ipsen Acquisition of Clementia Pharmaceuticals. February 25, 2019

Sustainability Learning Review 2015

Strategic Plan

ASX Investor Presentation

1Q 2015 Results A Positive Start to 2015

Itamar Medical. December Investors Presentation.

DRUG AND ALCOHOL TREATMENT ACTIVITY WORK PLAN

Introduction. Legislation & Policy Context

Acquisition of BP s Interests in Bruce, Keith and Rhum Fields in the North Sea Frequently Asked Questions

NATIONAL SUICIDE PREVENTION TRIAL ACTIVITY WORK PLAN

Forward Looking Information

Achieving Business Excellence, Role of Empowerment

Whole Of Society Approach To Preparedness

Operational Efficiency:

The Strategy Development Process. Global Fund and STOP TB Consultation Istanbul, Turkey 24 July 2015

Committed to Environment, Health, & Safety

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

The power of innovation to save lives

Cahoots Strategic Plan & Vision JULY 2017 JULY 2020

For personal use only

Prodent Introduction. Welcome

European map of investments in innovative digital solutions for AHA Early results

Report to the. GAVI Alliance Board June 2013

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Harm de Wildt MD TNI

POSITION DESCRIPTION. WCPT Programme Manager (SUDA Project) Victoria Charity Centre 11 Belgrave Road London SW1V 1RB, UK. Secondment option considered

TALKING POINTS INTRODUCTION

JOB SPECIFICATION FORM NO: HR-SOP Environment, Health & Safety Manager. Overview and Job purpose

Toward a healthier 2020

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Putting ALK on the right growth trajectory

The Chairman s report at William Demant Holding A/S annual general meeting on Thursday 22 March 2018 at 4 pm

Healthwatch Cheshire CIC Board Recruitment Information Pack

Photocure ASA Executing the Strategy

Gavi s private sector engagement approach

Welcome. A Legacy of Success. Brighter Futures Together

Aspirations Programme Quarterly Report Q3 (01 October 31 December 2018)

2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings

August 7, Q Financial Results

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Alertness and Sleep Health Management Research & Technology. Strategic Opportunity Overview

Food & Beverages Food for a growing world

Total Face Group Limited

Statement from International Transfusion Medicines Experts

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

BARNSLEY METROPOLITAN BOROUGH COUNCIL

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty

Connecticut Family Stability Pay for Success Project FACT SHEET

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

1. The World Bank-GAVI Partnership and the Purpose of the Review

UBS Australian Healthcare Conference 2013 Cochlear Limited. Chris Roberts, CEO 17 June 2013

GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE

Investor Presentation. October 2018

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

34 th Annual J.P. Morgan Healthcare Conference

Peer Support Worker Street to Home

DELIVERING OUR STRATEGY: FOR YOU, WITH YOU

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

CORPORATE PROFILE 2018

Transcription:

Managing Risk At Cochlear The Faculty Roundtable - Risky business workshop Karina Sharp - October 2013

Who are Cochlear? Global Footprint Global headquarters Regional office Mechelen Göteborg Denver Toronto London Paris Toulouse Bologna Hannover Basel Istanbul Beijing Shanghai Tokyo Seoul Hong Kong Panama Mumbai Singapore Direct operations in 20 countries Manufacturing in Australia and Sweden 2,500+ employees Listed on Australian Securities Exchange in 1995 - today top 100 Market cap over AU$3bn Cochlear Global Headquarters Sydney, Australia Cochlear Bone Anchored Solutions Gothenburg, Sweden Division of Cochlear Ltd Baha bone conduction solutions Brisbane Vistafix facial prosthesis R&D, Melbourne marketing, regulatory, manufacturing, quality, distribution, finance and admin support Over 140 employees Sydney

Cochlear Mission We help people hear and be heard. We empower people to connect with others and live a full life. We transform the way people understand and treat hearing loss. We innovate and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes.

Jonathon: 8 month old hears for the first time Sarah: 29 year old brought to tears

Cochlear Nucleus Systems Cochlear Hybrid Systems Cochlear Baha System Cochlear Codacs System Nucleus Cochlear Implant systems Hybrid Electro-Acoustic Implant systems Baha Bone Conduction Implant systems Codacs Direct Acoustic Cochlear Stimulation Implant systems

Cochlear Objectives Customer Experience Provide customers throughout their hearing journey with a convenient, seamless and consistent experience, delivering a lifetime of positive hearing outcomes. Operational Excellence Establish a dynamic agile operation with scalable, compliant and performance focussed processes, designed to deliver a positive experience for professionals and customers. Product Innovation Create and bring to market a segmented portfolio of innovative and quality products that combine leading technology with a strong focus on the context and needs of the professional and the customer to advance hearing outcomes. People Engagement Establish an organisation that attracts and retains the best people and engages and empowers them to take initiative and be accountable to deliver a positive experience for professionals and customers. Value Creation Create sustainable shareholder value, delivering high growth and strong returns today and into the future, while making a significant contribution to social good.

Cochlear Objectives - Measures Customer Experience Double the customer base over the next 5 years, growing at a rate greater than 15% per annum. Product Innovation Release a new (meaningful) product or service to market in each Category (Nucleus, Baha, Acoustic Implants) once every 12 months. Procurement s circle Operational Excellence Increase productivity, quality and outcomes of all business processes to achieve an EBIT margin of at least 30% of of concern / sphere of revenue. People Engagement Build influence our capabilities to execute the strategies and achieve our objectives, increasing engagement capital to be at the 75 th percentile of top performing global businesses. Value Creation Double annual revenue over the next 5 years, growing at a rate greater than 15% per annum and generating approximately AUD 1 billion in free cash flow.

What is Risk A probability or threat of damage, injury, liability, loss, or any other negative occurrence that is caused by external or internal vulnerabilities, and that may be avoided through pre-emptive action. Risk is different things to different organisations / and often it has multiple streams Strategic Compliance Financial Operational

Cochlear s Risk Profile 85% Singly sourced Proprietary Highly regulated Technologically constrained Low volume / spend High mix (externals / accessories) Material Obsolescence 85% of Supply base!

How Does Cochlear Manage Risk 4. Monitor / Measure 1. Supplier identification, selection & evaluation 2. Supplier Operational Risk assessment 3. BOM Re-use, Make, Buy assessment 4. Supplier performance reviews 1. Identify potential risk 3. Implement 5. Supplier Management (SCAR, CCC, SCN) 6. PIP - Procurement & Logistics readiness assessment 2. Categorize and select 3. Plan

Case Study Implantable IC proposed process flow

Risks Identified 10 year contract 25M EUR IMEC - distributor who could not provide evidence or demonstrate efficient and effective supply chain management practices 7 Supply chain partners 3 small private / independent organisations 11 shipments airfreighted across 6 countries 9 months lead time 12 months shelf life Variable yield: 40-60% at best Cost model structure Supply chain title and risk not clearly defined Development deliverable, timelines or transition to supply not clearly defined

Outcome Exit from Distributor move supply chain to Manufacturer Removes 4 supply chain partners: MFG in house capability Known supply partner, leverage portfolio spend and reduce cost Action plan to remove other supply chain partners Number of transits minimised reduces risk of damage in transit / exposure to moisture Consequence: 500K EUR compensation for loss of revenue opportunity agreed Identified Process / technology issues to be resolved in development phase Improve product yield Robust and repeatable process Scalable and sustainable supply chain

Lesson Learnt Project was started >6 years ago, no procurement involvement upfront = questions not asked risks not identified Be careful about what commitments are implied within a development phase Processes implemented to support projects will flesh out issues earlier Supplier relationship management Distributor still supplies product for our external device. Handled effectively and no impact realised Business realised procurements value proposition = raised awareness and increased collaboration inside and outside business frameworks

Questions or experiences you d like to share